Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease

American Journal of Epidemiology

Volumn 144, Issue 5, 1996, Pages 480-484

  Davis, J W ^a,b   Grandinetti, A ^b,c,d   Waslien, C I ^b   Ross, G W ^e   White, L R ^f   Morens, D M ^b,d  

^a Hawaii Osteoporosis Center   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c EAST WEST CENTER   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

mortality; Parkinson's disease; uric acid

Indexed keywords

URIC ACID;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARKINSON DISEASE; RISK; URIC ACID BLOOD LEVEL;

EID: 0029795479     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a008954     Document Type: Article

References (21)

1. Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981;78:6858-62.
2. Church WH, Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 1994;33:419-25.
3. Tohgi H, Abe T, Takahashi S, et al. The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993;6:119-26.
4. Worth RM, Kagan A. Ascertainment of men of Japanese ancestry in Hawaii through World War II Selective Service registration. J Chronic Dis 1970;23:389-97.
5. Yano K, Rhoads GG, Kagan A. Epidemiology of serum uric acid among 8000 Japanese-American men in Hawaii. J Chronic Dis 1977;30:171-84.
6. Grandinetti A, Morens DM, Reed D, et al. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994;139:1129-38.
7. Lee ET. Examining variables simultaneously - Cox's regression model for survival data. In: Statistical methods for survival data analysis. Belmont, CA: Wadsworth, Inc., 1980: 306-8.
8. Ellenberg JH. Differential postmorbidity mortality in observational studies of risk factors for neurologic disorders. Neuroepidemiology 1994;13:187-94.
9. Morens DM, Grandinetti A, Reed D, et al. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-51.
10. Morens DM, Grandinetti A, Davis JW, et al. Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson disease. Am J Epidemiol 1996; 144: 400-4.
11. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand Suppl 1991;136:6-15.
12. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-9.
13. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114 (Part 4):1953-75.
14. Sofic E, Paulus W, Jellinger K, et al. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991;56:978-82.
15. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982; 33:305-10.
16. Riederer P, Sofic E, Rausch W-D, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52;515-20.
17. Parkinson Study Group. DATATOP: a multi-center controlled clinical trial in early Parkinson's disease. Arch Neurol 1989; 46:1052-60.
18. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
19. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-12.
20. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40 (Suppl. 3):32-7.
21. Cohen G. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm Suppl 1983;19:89-103.